Séverine Banek

Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma

Yohann Loriot, Nobuaki Matsubara, Se Hoon Park et al. · New England Journal of Medicine · 2023 · 255 citations

Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial

Arlene O. Siefker‐Radtke, Nobuaki Matsubara, S.H. Park et al. · Annals of Oncology · 2023 · 69 citations · Full text

Metastatic Urothelial Cancer, Urology, Genitourinary Cancer +7

Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer

Daniel Groener, Cam Tu Nguyen, Justus Baumgarten et al. · EJNMMI Research · 2021 · 48 citations · Full text

Tumor-associated macrophages and Tregs influence and represent immune cell infiltration of muscle-invasive bladder cancer and predict prognosis

Florestan Koll, Séverine Banek, Luis Kluth et al. · Journal of Translational Medicine · 2023 · 47 citations · Full text

Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (<i>FGFRalt</i>).

Yohann Loriot, Nobuaki Matsubara, Se Hoon Park et al. · Journal of Clinical Oncology · 2023 · 44 citations

Fgfralt Muc, Pharmacotherapy, Lba4619 Background +20